Courage Therapeutics

Courage Therapeutics is a pre-clinical biotech company focused on feeding behavior. The company has established a platform for creating receptor subtype specific products to activate or block melanocortin pathway signaling. The company was founded to treat eating disorders such as anorexia nervosa and is a spin out of Dr. Roger Cone’s lab at work he University of Michigan. The Courage platform has established a series of proprietary clinical candidates with potent MC4R activity and MC3R antagonist activity to treat obesity and binge eating disorder. Courage is seeking to continue to develop additional orexigenic applications to support patients with challenges maintaining body weight due to metabo-psychiatric disorders.